Long-term safety and efficacy of deferasirox (Exjade (R)) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

Elliott Vichinsky*, Francoise Bernaudin, Gian Luca Forni, Renee Gardner, Kathryn Hassell, Matthew M. Heeney, Baba Inusa, Abdullah Kutlar, Peter Lane, Liesl Mathias, John Porter, Cameron Tebbi, Felicia Wilson, Louis Griffel, Wei Deng, Vanessa Giannone, Thomas Coates

*Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    69 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Long-term safety and efficacy of deferasirox (Exjade (R)) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease'. Together they form a unique fingerprint.

    Medicine and Dentistry